A retrospective real-world cohort study reports an 80.2% overall response rate for teclistamab in relapsed or refractory multiple myeloma patients treated primarily in community oncology clinics. The analysis included 101 patients and focused on outcomes across routine practice rather than tightly controlled trial settings. The results add to growing real-world experience with BCMA-targeting bispecifics, where response durability, treatment sequencing, and toxicity patterns can differ from clinical trial populations. Community delivery also highlights operational considerations such as access to step-up dosing, monitoring for cytokine-release syndrome, and post-treatment follow-up. As more centers adopt teclistamab, this dataset provides a practical benchmark for clinicians assessing expected response rates outside academic settings.